Kim S H, Evans C H, Kim S, Oligino T, Ghivizzani S C, Robbins P D
Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA.
Arthritis Res. 2000;2(4):293-302. doi: 10.1186/ar104. Epub 2000 May 24.
To determine whether IL-4 is therapeutic in treating established experimental arthritis, a recombinant adenovirus carrying the gene that encodes murine IL-4 (Ad-mIL-4) was used for periarticular injection into the ankle joints into mice with established collagen-induced arthritis (CIA). Periarticular injection of Ad-mIL-4 resulted in a reduction in the severity of arthritis and joint swelling compared with saline- and adenoviral control groups. Local expression of IL-4 also reduced macroscopic signs of joint inflammation and bone erosion. Moreover, injection of Ad-mIL-4 into the hind ankle joints resulted in a decrease in disease severity in the untreated front paws. Systemic delivery of murine IL-4 by intravenous injection of Ad-mIL-4 resulted in a significant reduction in the severity of early-stage arthritis.
为了确定白细胞介素-4(IL-4)对已确诊的实验性关节炎是否具有治疗作用,携带编码小鼠IL-4基因的重组腺病毒(Ad-mIL-4)被用于对已患胶原诱导性关节炎(CIA)的小鼠踝关节进行关节周围注射。与生理盐水和腺病毒对照组相比,Ad-mIL-4的关节周围注射导致关节炎严重程度和关节肿胀减轻。IL-4的局部表达也减少了关节炎症和骨侵蚀的宏观体征。此外,将Ad-mIL-4注射到后踝关节导致未治疗的前爪疾病严重程度降低。通过静脉注射Ad-mIL-4进行小鼠IL-4的全身递送导致早期关节炎严重程度显著降低。